Patents by Inventor Kellie Kozak Vaidya

Kellie Kozak Vaidya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibition of dendritic cell-driven regulatory T cell activation and potentiation of tumor antigen-specific T cell responses by interleukin-15 and MAP kinase inhibitor
    Patent number: 10443039
    Abstract: The invention involves the discovery that if dendritic cells loaded with a tumor antigen are cultured in interleukin-15 (IL-15), or if T cells activated by the dendritic cells are cultured in IL-15, Treg activity that is specific for the tumor antigen is reduced. This reduction in Treg activity results in an increase in anti-tumor immune response. Another embodiment of the invention involves the discovery that incubating dendritic cells with a MAP kinase inhibitor in combination with IL-15 gives synergistic benefits when the dendritic cells are used to activate T cells. Dendritic cell and T cell compositions incubated with IL-15 or a MAP kinase inhibitor are provided.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: October 15, 2019
    Assignee: Bioventures, LLC
    Inventors: Martin J. Cannon, Kellie Kozak Vaidya, Timothy J. O'Brien
  • Inhibition of Dendritic Cell-Driven Regulatory T Cell Activation and Potentiation of Tumor Antigen-Specific T Cell Responses by Interleukin-15 and MAP Kinase Inhibitor
    Publication number: 20140037579
    Abstract: The invention involves the discovery that if dendritic cells loaded with a tumor antigen are cultured in interleukin-15 (IL-15), or if T cells activated by the dendritic cells are cultured in IL-15, Treg activity that is specific for the tumor antigen is reduced. This reduction in Treg activity results in an increase in anti-tumor immune response. Another embodiment of the invention involves the discovery that incubating dendritic cells with a MAP kinase inhibitor in combination with IL-15 gives synergistic benefits when the dendritic cells are used to activate T cells. Dendritic cell and T cell compositions incubated with IL-15 or a MAP kinase inhibitor are provided.
    Type: Application
    Filed: September 30, 2013
    Publication date: February 6, 2014
    Applicant: The Board of Trustees of the University of Arkansas
    Inventors: Martin J. Cannon, Kellie Kozak Vaidya, Timothy J. O'Brien